Understanding Anti-Obesity Drugs: Their History, Types and Effectiveness
The Rise of Weight Loss Medications
Since the prevalence of obesity increased dramatically in the late 20th century, pharmaceutical companies began actively researching and developing prescription medications specifically for weight loss. The first anti-obesity medication approved for long-term use was sibutramine, sold under the brand name Meridia. Released in 1997, sibutramine works to reduce appetite by inhibiting the reuptake of serotonin and norepinephrine. However, sibutramine was later withdrawn from markets in 2010 due concerns over increased risk of heart attack and stroke. Orlistat, marketed as Xenical and Alli, was approved by the FDA in 1999. Orlistat works by inhibiting gastric and pancreatic lipases, enzymes that help break down fat during digestion. By blocking approximately 30% of fat absorption, orlistat modestly reduces weight through lowered caloric intake.
Current Prescription Medications
While sibutramine and orlistat paved the way, newer anti-obesity medications have been introduced that target specific pathways involved in appetite regulation and metabolism. Belviq (lorcaserin), released in 2012, selectively activates serotonin 2C receptors in the brain to reduce appetite. Qsymia (phentermine and topiramate extended-release) combines an appetite suppressant similar to amphetamine with an anti-seizure/migraine preventative medication and was approved in 2012. Saxenda (liraglutide) is a glucagon-like peptide-1 (GLP-1) analog that suppresses appetite through glycemic control and was greenlit for weight management in 2014. Wegovy (semaglutide 2.4mg), another GLP-1 analog, received FDA approval for chronic weight management in 2021 and induces greater weight loss than Saxenda. These medications are intended for use alongside lifestyle modification in adults who are obese or overweight with weight-related conditions.
Combination Therapy and New Pathways
Given the multifactorial nature of obesity, experts argue combination pharmacotherapy may be preferable to targeting a single pathway. Some of the most promising trials have evaluated different combinations of current anti-obesity medications, finding greater weight loss versus monotherapy. For instance, trials pairing Belviq with Qsymia or phentermine showed superior reductions in body weight and waist circumference. Researchers are also exploring alternative pathways such as MC4R agonism, 5-HT2C potentiators, and fat cell apoptosis induction as targets for the next generation of Anti-Obesity Drugs . Others advocate for gut microbiome modulation through prebiotics/probiotics or fecal transplants. While still experimental, emerging research on the microbiome-gut-brain axis in appetite regulation raises hopes these approaches could aid established pharmaceutical interventions in the future.
Efficacy and Safety Concerns
On average, FDA-approved weight loss medications help individuals lose 3-9% of their body weight over 6-12 months of treatment. Most reviews find these medications more than double diet and lifestyle-induced weight loss. However, their efficacy varies between individuals and waning effects occur once medication is stopped if no lifestyle changes stick. Side effects are also a limitation, with some reporting gastrointestinal issues, headache, dry mouth, and rare psychiatric effects. As with any chronic medical therapy, safety monitoring and individual risk-benefit assessments are essential considerations when determining appropriate usage periods. Long-term cardiovascular outcomes data is also still limited for newer drugs like Wegovy. With obesity rates still growing globally, continuing to expand safe and effective pharmacotherapy remains a public health priority.
Get more insights on - Anti-Obesity Drugs
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian